Bausch + Lomb (NYSE:BLCO) Director Sells $206,250.00 in Stock

Bausch + Lomb Corporation (NYSE:BLCO) Director Eschenbach Andrew Von sold 12,500 shares of the stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $16.50, for a total value of $206,250.00. Following the completion of the sale, the director directly owned 69,792 shares of the company’s stock, valued at $1,151,568. The trade was a 15.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Bausch + Lomb Stock Performance

Shares of BLCO opened at $16.81 on Thursday. The company has a current ratio of 1.55, a quick ratio of 1.02 and a debt-to-equity ratio of 0.79. The firm has a market cap of $6.00 billion, a PE ratio of -35.02, a price-to-earnings-growth ratio of 0.55 and a beta of 0.56. The company’s 50 day simple moving average is $16.13 and its 200-day simple moving average is $16.39. Bausch + Lomb Corporation has a 12-month low of $13.77 and a 12-month high of $18.92.

Wall Street Analyst Weigh In

BLCO has been the topic of a number of recent research reports. HC Wainwright lifted their price objective on shares of Bausch + Lomb from $20.00 to $21.00 and gave the company a “buy” rating in a research note on Monday, August 3rd. Evercore set a $17.00 target price on shares of Bausch + Lomb in a research note on Monday, July 6th. Citigroup raised their price target on Bausch + Lomb from $19.00 to $21.00 and gave the stock a “buy” rating in a report on Wednesday, July 8th. Wall Street Zen upgraded Bausch + Lomb from a “hold” rating to a “buy” rating in a research report on Saturday, April 18th. Finally, Weiss Ratings downgraded Bausch + Lomb from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, August 7th. Five equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $18.75.

Hedge Funds Weigh In On Bausch + Lomb

Institutional investors have recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd lifted its stake in shares of Bausch + Lomb by 104.1% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 2,227 shares of the company’s stock worth $38,000 after acquiring an additional 1,136 shares during the period. Northwestern Mutual Wealth Management Co. increased its stake in shares of Bausch + Lomb by 729.3% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 2,322 shares of the company’s stock worth $30,000 after acquiring an additional 2,042 shares during the period. Royal Bank of Canada increased its stake in shares of Bausch + Lomb by 67.1% during the first quarter. Royal Bank of Canada now owns 3,657 shares of the company’s stock worth $58,000 after acquiring an additional 1,468 shares during the period. Wells Fargo & Company MN increased its stake in shares of Bausch + Lomb by 31.2% during the fourth quarter. Wells Fargo & Company MN now owns 5,903 shares of the company’s stock worth $101,000 after acquiring an additional 1,403 shares during the period. Finally, Invesco Ltd. purchased a new position in Bausch + Lomb during the fourth quarter worth about $178,000. 11.07% of the stock is owned by institutional investors and hedge funds.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.